Our analysis of B cells in prostate tumors in this study lays the groundwork for future clinical trials in which we plan to use this method to quantify B cells along with other pathologic data or staining of additional markers such as CXCL13, IKKα and BMI1 that were identified in the murine preclinical studies into more quantitative analysis in patients [11,12]. Here, CXCL13 is linked to prostate neoplasm.